- Types of Eczema
- Child Eczema
- Causes & Triggers
- Living with Eczema
- Eczema Products
- Get Involved
When Gideon Park’s young daughter developed eczema, his family looked high and low for answers. “It has been a long, confusing, and heartbreaking year of watching her itch; learning the ins and outs or triggers, trying all sorts of steroids, antihistamines, creams, soaps, and moisturizers; and negotiating conflicting advice.” At NEA, we know managing eczema […]
… I am a woman surviving it. Who calls into work sick because of eczema? That’s what I’m sure people thought when I was consistently missing work due to lack of sleep, broken and bleeding skin, and sometimes just feeling too emotionally unstable to hold it together in the office. I was doing my best […]
Understanding AD’s impact to improve your quality of life People living with atopic dermatitis (AD), the most common and chronic form of eczema, know first-hand the burden AD has on both individuals and families. The impacts reach far beyond the serious effects of the disease symptoms such as itch, pain, and inflammation –they also include […]
Eczema affects more than 30 million people in the United States. The most common and chronic form of eczema is known as atopic dermatitis (AD). There is currently no cure for eczema or AD. To help raise awareness about the serious impact AD has on individuals and families, the National Eczema Association (NEA) has joined […]
We asked, you answered. The verdict? People living with eczema want more information and more options. This past January, many of you responded to a 6-question online survey to evaluate patient satisfaction and the role of doctors in the treatment of the most serious form of eczema, atopic dermatitis (AD). We learned that the vast majority of […]
June 9, 2016 – On Monday, June 6, 2016 the pharmaceutical companies Regeneron and Sanofi, reported positive results for the Phase 3 the clinical trial of the new biologic drug, dupilumab, when used in conjunction with a topical corticosteroid by adults to treat moderate-to-severe atopic dermatitis (AD).
February 11, 2016 – Late last month, NEA’s Board of Directors gathered together for the annual NEA Board retreat in San Francisco, California. This year’s retreat focused on both celebrating 2015 successes, and sharing a number of exciting 2016 initiatives that will advance NEA’s Roadmap strategic plan goals.
February 10, 2016 – In January, Anacor Pharmaceuticals, Inc. announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of crisaborole topical ointment, 2%.
January 11, 2016 – We need to hear from you! We are launching a series of short surveys to make certain we best understand the challenges you face with eczema. Together, we will use this information to fight for your needs, whether you’re an adult with eczema, a child, or parent on the eczema journey. The information you share will shape NEA’s policy priorities for 2016 and beyond, and help us better tell the collective stories about the impact eczema has on your lives.
November 3, 2015 – A research team at Emory University was awarded a NEA Research Grant for their pilot study of the efficacy of meditation for treatment of chronic pruritus (itch). Following is an interview about the study and results, with investigators Mamta Javari, MD, and Suephy Chen, MD.